左西孟旦治疗高龄老年终末期心力衰竭疗效评价

目的观察左西孟旦治疗高龄老年终末期心力衰竭患者的临床效果及安全性。方法符合纳入标准的56例高龄老年心衰患者被随机分成常规治疗组和左西孟旦＋常规治疗组。观察两组治疗前后的临床疗效、心功能,测定NT-pro BNP,SV,LVEF等指标,并进行安全性分析。结果左西孟旦组显效率、有效率和总有效率均高于常规治疗组（P〈0.05）;左西孟旦治疗在降低NT-pro BNP,改善SV,LVEF方面均显著优于常规治疗组（P〈0.05）,两组不良反应发生率差别无统计学意义（P〉0.05）,未发生严重不良事件,常见不良反应为低血压、食欲不振、头昏。结论左西孟旦治疗高龄老年终末期心力衰竭患者,可明显改善其血流动力学指标,提高心功能,改善心力衰竭的症状,安全性及耐受性良好。

End-stage heart failure efficacy of levosimendan in the treatment of the elderly

Objectives To observe the effect of levosimendan in the treatment of elderly patients with end-stage heart failure clinical efficacy and safety.Methods 56 cases of senile heart failure patients meet the inclusion criteria were randomly divided into routine treatment group and levosimendan and conventional therapy group.To observe the clinical efficacy of the two groups before and after treatment,the heart function,the determination of NT-proBNP,SV,LVEF and other indicators,and security analysis.Re-sults The levosimendan group of significant efficiency,efficiency and total effective rate were higher than normal group（P〈0.05）;levosimendan treatment in reducing NT-proBNP,improved SV,LVEF is obviously superior to the conventional treatment group（ P〈0.05）,adverse reactions of two groups was no significant difference（P〉0.05）,no serious adverse events,the most common adverse events are hypotension,anorexia,dizziness.Conclusions levosimendan in the treatment of elderly patients with end-stage heart fail-ure,can significantly improve the hemodynamics,improve heart function,improve the symptoms of heart failure,good safety and toler-ability.